Immix Biopharma (IMMX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IMMX Immix Biopharma

Watchlist

1.590
-0.010-0.63%

Close Nov 1 16:00 ET

43.65MMarket Cap-1915P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook
TipRanksOct 3 06:16 ET · Ratings
Immix Biopharma: Ex-US Study of NXC-201 Produced 92% ORR in R/r AL Amyloidosis
TipRanksOct 2 09:35 ET
Express News | Immix Biopharma Inc: Now Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells
ReutersOct 2 09:33 ET
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
GlobeNewswireOct 2 09:32 ET
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
GlobeNewswireSep 19 09:31 ET
Express News | Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
ReutersSep 19 09:31 ET

Comments

Stock_Drift

Oct 2 10:07

$Immix Biopharma (IMMX.US)$

Stock_Drift

Sep 19 09:57

$Immix Biopharma (IMMX.US)$

Jaguar8

Aug 28 08:32

NEWS

$Immix Biopharma (IMMX.US)$
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunit...

Jaguar8

Jul 25 20:38

NEWS: California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8M

$Immix Biopharma (IMMX.US)$
Immix Biopharma (Nasdaq: IMMX) has been awarded an $8 million CLIN2 grantfrom the California Institute for Regenerative Medicine (CIRM) to support the clinical development of NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. The funding will be used for the NEXICART-2 U.S. clinical trial, which aims to evaluate the...